Home   News   Article

Queen Elizabeth Hospital staff contribute to medical device award



More news, no ads

LEARN MORE


Staff at Lynn’s hospital contributed to an innovative medical device which has won a well-respected award.

Medovate, a Cambridge-based medical company, has announced its device SAFIRA (SAFer Injection for Regional Anaesthesia) has won an award at Global Health and Pharma’s Healthcare and Pharmaceutical Awards 2020.

The device provides a revolutionary solution that limits injection pressure, helping to improve patient safety by reducing the risk of nerve damage in patients resulting from injection at high pressures.

Pictured from left to right are Stuart Thomson, managing director of Medovate; Dr Peter Young, critical care consultant and co-inventor of SAFIRA; Dr Antonia Hardcastle, head of education, learning and research; Dr John Gibson, critical care consultant and co-inventor of SAFIRA and Mr Cristian Ilie, director R&D. Picture: SUBMITTED
Pictured from left to right are Stuart Thomson, managing director of Medovate; Dr Peter Young, critical care consultant and co-inventor of SAFIRA; Dr Antonia Hardcastle, head of education, learning and research; Dr John Gibson, critical care consultant and co-inventor of SAFIRA and Mr Cristian Ilie, director R&D. Picture: SUBMITTED

And the company worked closely with consultant anaesthetists Dr Peter Young, Dr Emad Fawzy, Dr Joseph Carter and Dr John Gibson from the Queen Elizabeth Hospital during the development of SAFIRA.

Dr Gibson said: “Nerve injury is a complication that can arise from regional anaesthesia and is a potentially life changing injury.

“SAFIRA was developed to put control of the injection in the hands of the anaesthetist, and to reduce as far as is possible these variables.

“The device allows the anaesthetist to position the needle as usual and then control the aspiration and injection of local anaesthetic and will not allow the injection to proceed if the pressure within the syringe goes above a certain threshold level.”

Current practice requires two operators, an anaesthetist to hold an ultrasound probe in one hand and a nerve block needle in the other.

An assistant operates a syringe to inject the anaesthetic solution at a required pressure.

This is highly subjective, and ‘syringe feel’ varies between individuals.

By giving the anaesthetist full control of the injection, SAFIRA enables consistent, reliable flow and pressure of anaesthetic during a regional block procedure.

Medovate’s latest award reflects the company’s mission to bring to life essential new technologies that can realise improved outcomes for patients across the world.

Managing director Stuart Thomson said: “Since we were established three-years-ago, our focus has been to develop and commercialise innovative medical technologies to benefit the areas of anaesthesia, airway management, critical care and surgery, which currently present a number of unmet needs and challenges pertaining to patient safety.

“We are incredibly proud that our technology has been recognised at this year’s Healthcare and Pharmaceutical Awards for the benefits it can bring to regional anaesthesia as a unique device which helps to reduce the risk of patient nerve injury.”

Entries for the 2020 awards were open from June 8 to August 3.



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More